Search

Patients undergoing cardiac transplantation are at increased risk of dyslipidemia (60% to 80%). Lipid-lowering treatment in these patients should be aggressive given the known role of dyslipidemia in chronic transplant rejection. The objective of this study was to evaluate the efficacy and safety of pravastatina therapy and its effect upon cyclosporine levels in a population of dyslipidemic cardiac transplant patients.A total of 20 cardiac transplant patients were enrolled in this 39-week length prospective observational study. Patients had serum cholesterol levels exceeding 200 mg/dl, and received pravastatin therapy at the adequate dose to obtain an optimal lipid profile without significant adverse effects. Pravastatin, at a mean dose of 50 18 mg/day, produced a significant reduction in total cholesterol levels (from 291 32 to 203 25 mg/dl, p < 0.05), LDL cholesterol (from 187 34 to 102 15 mg/dl, p < 0.05) and an increase in HDL-cholesterol levels (from 48 16 to 55 14, p < 0.05). A slight asymptomatic increase in CPK levels was observed but no differences in cyclosporine levels. Pravastatin has shown to be an effective and safe therapy in dyslipidemic cardiac transplant patients.

Since the Spanish Society of Cardiology Clinical Practice Guidelines on Unstable Angina/Non-Q-Wave Myocardial Infarction were released in 1999, the conclusions of several studies that have been published make it advisable to update current clinical recommendations. The main findings are related to the developing role of Chest Pain Units in the management and early risk stratification of acute coronary syndromes in the emergency department; new information concerning the efficacy of glycoprotein IIb/IIIa inhibitors, clopidogrel and low-molecular-weight heparins in the pharmacological treatment of acute coronary syndromes without ST-segment elevation; and the role of early invasive strategy in improving the prognosis of these patients. The published evidence is reviewed and the corresponding clinical recommendations for the management of acute coronary syndromes without persistent ST-segment elevation are updated.

This paper up-dates the Clinical Guidelines for Unstable Angina/Non Q wave Myocardial Infarction of the Spanish Society of Cardiology. Due to the increased efficacy of adequate management in the early phases, it has been considered necessary to include recommendations for the pre Hospital and Emergency department phase. Prehospital management. Patients with thoracic pain compatible with myocardial ischemia should be transferred to Hospital as quickly as possible and an ECG tracing performed. Initial management includes rest, sublingual nitroglycerin and aspirin. In the Emergency department. Immediate clinical attention and accessibility to a defibrillator should be available. If ECG tracing discloses ST elevation reperfusion strategy is to be implemented immediately. If no ST elevation is present, the probability of myocardial ischemia and risk factor evaluation is essential for adequate management. A simplified risk stratification classification is presented, that also determines the most adequate site for admission: Coronary Care Unit if high risk factors are present, Cardiology ward for the intermediate risk patient and ambulatory treatment if low risk. Management in Coronary Care Unit. Includes routine ECG monitoring and analgesia. Antithrombotic and anti ischemic treatment include new indication for GP IIb-IIIa and Low molecular weight heparins. Coronary arteriography and revascularisation are recommended, if refractory or recurrent angina, left ventricles dysfunction or other complications are present. Management in the ward is based on adequate chronic medical treatment, risk stratification, and secondary prevention strategy. Coronary arteriography before discharge must be considered in the light of the result of non-invasive tests.

Objective: To gather information about efficacy and tolerability of nifedipine GITS in patients with stable angina, and its impact on the patient quality of life., Patients and Methods: 1076 patients of both sexes (63.5 +/- 12.8 year old) with stable angina (classes I to III of the CCVS) and evidence of coronary disease (43.3% previous myocardial infarction) were included. The treatment with nifedipine GITS 30-60 mg/day (monotherapy or combination) lasted for 6 months. The study variables were: weekly rate of anginal attacks, short-acting nitrate consumption, changes in the antianginal drug treatment, tolerability, and changes in the questionnaire score concerning the quality of life., Results: A decrease in the number of the anginal attacks and in the short-acting nitrates consumption by 80.7% and 83.3%, respectively (both, p = 0.001), was found. Furthermore, the proportion of patients experiencing anginal attacks the week before the assessment visit fell from 71.7% to 10.9% (p < 0.001). At the end of the study, a remarkable decrease in the use of other antianginal medications was seen. Side effects were reported by 10.9% of the patients, 2.7% of which were withdrawn from the study for this reason. A favourable change in the patient quality of life was also noted., Conclusion: In patients with stable angina, nifedipine GITS is an effective, safe and well tolerated drug that remarkably enhances the patient quality of life.

Objective: To ascertain whether a given level of antimyosin monoclonal antibody (AMA) uptake in the endomyocardial biopsy (EMB) can identify patients with rejection., Material and Method: 186 examinations were performed on 65 patients (8 women and 57 men) with orthotopic heat transplant (HT): Mean age 51 +/- 13 years. There were 3 examinations per patient (range 1-6). The studies were conducted 13 to 880 days after the HT. The C/p uptake indexes were obtained according to the Carrió y cols. method and the results were compared with the biopsy findings. Rejection was considered to be when the biopsy showed at least one site of necrosis., Results: 1) We analyzed the C/P index in accordance with the post-HT interval and with the degree of rejection obtained by EMB. No group showed any significant differences between the patients with an without rejection (p > 0,05). 2) We applied a variable threshold based on post-HT interval, using an exponential curve defined on the basis of the interval of the values corresponding to patients without rejection and good progress compared with that of the rejection patients. This approach also did not contribute any improvement compared to the use of a fixed threshold due to the significant overlay of the values for patients with and without rejection. 3) Finally, we analyzed the individual evolution of the C/P indexes for each patient in terms of time. In patients whose clinical progress was good, the C/P indexes were observed to drop progressively over time. In those whose clinical progress was poor, abrupt increases in the index values were observed., Conclusion: We were unable to differentiate significantly between patients with and without rejection in EMB using fixed and variable thresholds of the C/P index. However, the different patterns of evolution for each patient provide information on the lack of complications and could be used as a follow-up technique.

Myocardial bridges consist of muscle fiber bundles lining an epicardial coronary artery for a variable distance. They are a relatively common finding, with incidence changing on the basis of the study method used (angiographic/necropsy). Although myocardial bridges are usually associated with a benign prognosis, being in many cases asymptomatic and only found by chance, their presence has also been considered a cause of angina, malignant arrhythmia, myocardial infarction and sudden death. They are diagnosed in vivo by angiography when a systolic compression of a coronary artery which disappears during diastole is evidenced. We report the case of a patient with electrocardiographic signs of severe ischemia in the territory of the anterior descending artery, which was initially assessed as myocardial infarction and treated as such. Eventually, the ECG returned to normal, and no new Q waves of necrosis occurred. An angiohemodynamic study confirmed the existence of an isolated muscular bridge over the middle third of the anterior descending artery, with no other associated coronary lesions.

Insufficiency on the tricuspid valve alone due to cardioarticular rheumatism is a rare condition. A 12-year-old boy had had six episodes of rheumatic fever over the previous 5 years. The only damage done to the heart was insufficiency of the tricuspid valve; none of the other valves were affected. The phonocardiographic response to the amyl nitrate and methoxamine tests as well as the correct evaluation of the jugular phlebogram confirmed the diagnosis of this valve pathology. The study of this heart condition was completed with the diagnosis of rheumatic fever (Jones' criteria, modified) and an angiohemodynamic evaluation of the patient (which must include left and right ventriculography using a Bourassa catheter on the right). This pathology is extremely rare and we have found no reference to it in the literature in this country.